Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
Lupin gets EIR from US FDA for Nagpur-based injectable facility
Lupin gets EIR from US FDA for Nagpur-based injectable facility
Read also
UK approves GSK's twice-yearly asthma drug
Reuters - UK's health regulator on Monday approved GSK's (GSK.L), opens new tab twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as fo...
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
Sumitomo Pharma Presents Encouraging New Data on DSP-5336
Sumitomo Pharma Presents Encouraging New Data on DSP-5336 Clinical Activity at the American Society of Hematology Annual Meeting
First gonorrhoea antibiotics in decades herald new era of treatment
Entasis’ Nuzolvence and GSK’s Blujepa are the first antibiotic approvals in gonorrhoea in over 30 years in the US.
